MGX
Metagenomi Inc.

788
Mkt Cap
$65.33M
Volume
426,680.00
52W High
$4.40
52W Low
$1.23
PE Ratio
-0.73
MGX Fundamentals
Price
$1.65
Prev Close
$1.74
Open
$1.74
50D MA
$2.29
Beta
1.01
Avg. Volume
434,773.21
EPS (Annual)
-$2.09
P/B
0.37
Rev/Employee
$258,886.14
Loading...
Loading...
News
all
press releases
Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Rating of "Moderate Buy" from Brokerages
Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) has received a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, MarketBeat Ratings reports. One research...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Bank of America resets Amazon stock forecast after key meeting
Amazon stock has lost about 8% in a month, despite ending October with a very strong earnings report. The drop in the stock's value is due to artificial intelligence stocks being hit with a sell-off...
TheStreet.com·9d ago
News Placeholder
Metagenomi, Inc. (NASDAQ:MGX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Metagenomi, Inc. (NASDAQ:MGX - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·27d ago
News Placeholder
Metagenomi (NASDAQ:MGX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Metagenomi (NASDAQ:MGX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of...
MarketBeat·29d ago
News Placeholder
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.read more...
Benzinga·1mo ago
News Placeholder
Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates
Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of +4.17% and +242.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +19.68% and +10.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy
Does Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·2mo ago

Latest MGX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.